Evestia Clinical, a global independent specialist contract research organization (CRO), has announced the acquisition of Berlin-based ICRC-Weyer GmbH, a long-established CRO and scientific consultancy with strong expertise in data-driven clinical research.

The acquisition significantly strengthens Evestia Clinical’s footprint in Germany and across Europe, while expanding its full-service clinical research capabilities for biotechnology innovators. ICRC-Weyer adds deep specialist expertise in biostatistics, data management and medical writing, capabilities that are increasingly critical as clinical trial complexity and regulatory scrutiny continue to rise.

Founded in 1993, ICRC-Weyer brings decades of scientific and operational experience across the full clinical development lifecycle, including early- and late-phase studies, adaptive trial designs, medical device research, and post-marketing activities. Its integration enhances Evestia Clinical’s European presence and provides biotech clients with broader access to high-quality, end-to-end clinical development services.

Clients of ICRC-Weyer will gain access to Evestia Clinical’s global clinical trial capabilities spanning Phase I to Phase III and beyond. The combined offering delivers more integrated support across key therapeutic areas such as oncology, neurology and rare diseases.

Richard Barfield, Chairman of Evestia Clinical, said the acquisition marks an important milestone as the company completes one year since its launch and advances its strategy to build a truly global specialist CRO. He noted that the expanded capabilities reinforce Evestia Clinical’s position as a trusted partner for biotech innovators developing complex therapies.

Chief Executive Officer Lewis Cameron added that the acquisition strengthens operational delivery in Europe and complements the company’s existing presence in Spain, Italy and France, alongside its growing footprint in the United States.

Johann Daniel Weyer, Managing Director of ICRC-Weyer, said joining Evestia Clinical creates a stronger and more comprehensive platform to support increasingly complex clinical development programs across Europe and beyond.

Financial terms of the transaction were not disclosed. ICRC-Weyer will continue to operate under its existing brand, with no changes to its services or team. Johann Daniel Weyer will join the Evestia Clinical leadership team as part of the integration.